Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer

Imagem de Miniatura
Arquivos
art_PANIS_Early_downregulation_of_acute_phase_proteins_after_doxorubicin_2016.PDF (518.85 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
PANIS, Carolina
PIZZATTI, Luciana
BUFALO, Aedra Carla
HERRERA, Ana Cristina
CECCHINI, Rubens
ABDELHAY, Eliana
Citação
TUMOR BIOLOGY, v.37, n.3, p.3775-3783, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic-proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m(2)) and processed for label-free LC-MS proteomic screening. A total of 80 proteins were downregulated after chemotherapy. In silico analysis revealed that the main biological process enrolled was inflammation and canonical pathways involving acute phase proteins. TNF-alpha, IL-1 beta, IL-12, TGF-beta 1, clusterin, and gelsolin were chosen as relevant for further validation. All selected targets presented reduced plasmatic levels after treatment. Our results indicate that doxorubicin downregulated acute phase proteins immediately after its infusion. Since such proteins are cancer promoting, its downregulation could support the effectiveness of doxorubicin along treatment.
Palavras-chave
Breast cancer, Doxorubicin, Label-free proteomics, Cytokines, Acute phase proteins, Downregulation
URI
https://observatorio.fm.usp.br/handle/OPI/14409
Referências
  1. Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109
  2. Hamaguchi T, 2011, BIOCHEM BIOPH RES CO, V407, P525, DOI 10.1016/j.bbrc.2011.03.051
  3. Ham M, 2013, ARCH PHARM RES, V36, P1419, DOI 10.1007/s12272-013-0271-7
  4. Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
  5. Cecilio AP, 2015, BREAST CANCER-TARGET, V7, P43, DOI 10.2147/BCTT.S50361
  6. Panis C, 2014, J PROTEOME RES, V13, P4752, DOI 10.1021/pr500676x
  7. Ansar W, 2013, IMMUNOL RES, V56, P131, DOI 10.1007/s12026-013-8384-0
  8. Panis C, 2015, CANCER LETT, V357, P186, DOI 10.1016/j.canlet.2014.11.029
  9. Djeu JY, 2009, ADV CANCER RES, V105, P77, DOI 10.1016/S0065-230X(09)05005-2
  10. Noguchi Y, 1996, SURG TODAY, V26, P467
  11. Niu ZH, 2013, EUR REV MED PHARMACO, V17, P1337
  12. Chen ST, 2002, CANCER LETT, V181, P95, DOI 10.1016/S0304-3835(02)00025-3
  13. Kumar SN, 2011, J PROTEOMICS, V74, P683, DOI 10.1016/j.jprot.2011.02.013
  14. Lee SH, 2012, MOL MED REP, V6, P157, DOI 10.3892/mmr.2012.879
  15. Panis C, 2013, CURR PROTEOMICS, V10, P136
  16. Panis C, 2012, BREAST CANCER RES TR, V133, P881, DOI 10.1007/s10549-011-1851-1
  17. Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6
  18. Tisdale Michael J, 2003, J Support Oncol, V1, P159
  19. Kono H, 2014, CURR OPIN IMMUNOL, V26, P147, DOI 10.1016/j.coi.2013.12.004
  20. Panis C, 2014, ADV PROTEIN CHEM STR, V94, P19, DOI 10.1016/B978-0-12-800168-4.00002-0
  21. McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
  22. Lakota K, 2011, AUTOIMMUN REV, V10, P779, DOI 10.1016/j.autrev.2011.06.001
  23. Falgarone G, 2009, ADV CANCER RES, V104, P139, DOI 10.1016/S0065-230X(09)04008-1
  24. Pensa S, 2009, J MAMMARY GLAND BIOL, V14, P121, DOI 10.1007/s10911-009-9124-x
  25. van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023
  26. FRUEHAUF JP, 1992, ONCOL RES, V4, P91
  27. Kim ES, 2014, ONCOGENE, V33, P3583, DOI 10.1038/onc.2013.319
  28. Panis C, 2013, CANCER LETT, V330, P57, DOI 10.1016/j.canlet.2012.11.020
  29. Schwartz Y, 2008, BREAST CANCER RES TR, V107, P211, DOI 10.1007/s10549-007-9540-9
  30. Li GH, 2012, MED RES REV, V32, P999, DOI 10.1002/med.20231
  31. Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946
  32. Suswam EA, 2005, INT J CANCER, V113, P911, DOI 10.1002/ijc.20675
  33. Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829
  34. Buranrat B, 2015, ONCOL REP, V34, P2790, DOI 10.3892/or.2015.4250
  35. Chew E, 2001, W J MED, V174, P284
  36. Coventry BJ, 2009, TRANSL MED, V7, P102
  37. Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001
  38. Michlmayr A, 2010, BRIT J CANCER, V103, P1201, DOI 10.1038/sj.bjc.6605909
  39. Pizzatti L, 2012, PROTEOMICS, V12, P2618, DOI 10.1002/pmic.201200066
  40. Priestman T J, 1975, Clin Oncol, V1, P207
  41. Sparano JA, 2009, J CLIN ONCOL, V20, P4522
  42. Stephens Nathan A, 2008, Curr Opin Support Palliat Care, V2, P267, DOI 10.1097/SPC.0b013e3283186be2
  43. Zarzynska JM, 2014, MEDIAT INFLAMM, V2014, P1, DOI 10.1155/2014/141747

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/51
Artigos e Materiais de Revistas Científicas - ODS/03